1-9 of 9
Volker Heinemann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)

Arndt Stahler, Andreas J. Kind, Christine Sers, Soulafa Mamlouk, Lothar Müller, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Ludwig Fischer von Weikersthal, Greta Sommerhäuser, Stefan Kasper, Beeke Hoppe, Annika Kurreck, Swantje Held, Volker Heinemann, David Horst, Armin Jarosch, Sebastian Stintzing, Tanja Trarbach, Dominik P. Modest
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1256–1263.
https://doi.org/10.1158/1078-0432.CCR-23-3023
Published: 01 April 2024
View article titled, Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212)
Open the PDF for Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212) in another window
Includes: Supplementary data
Journal Articles

Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score

C. Benedikt Westphalen, Alexander D. Fine, Fabrice André, Shridar Ganesan, Volker Heinemann, Etienne Rouleau, Clare Turnbull, Luis Garcia Palacios, Jorge-Antonio Lopez, Ethan S. Sokol, Joaquin Mateo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1412–1421.
https://doi.org/10.1158/1078-0432.CCR-21-2096
Published: 01 April 2022
View article titled, Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score
Open the PDF for Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score in another window
Includes: Supplementary data
Journal Articles

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

Antje Wick, Oliver Bähr, Martin Schuler, Kristoffer Rohrberg, Sant P. Chawla, Filip Janku, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz-Josef Lenz, Masafumi Ikeda, Yuichi Ando, Wolfgang Wick, Joachim P. Steinbach, Michael C. Burger, Katharina Wenger, Ulrik Lassen, Kamalesh K. Sankhala, Cristiana Roggia, Isabelle Genvresse, Catya Munhoz, Christine Rentzsch, Susanne Reschke, Simon Langer, Markus Wagner, Stefan Kaulfuss, Charles Cai, Eleni Lagkadinou, Michael Jeffers, Carol Peña, Ghazaleh Tabatabai
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2723–2733.
https://doi.org/10.1158/1078-0432.CCR-20-4256
Published: 15 May 2021
View article titled, Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
Open the PDF for Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials

Arndt Stahler, Sebastian Stintzing, Dominik P. Modest, Ingrid Ricard, Clemens Giessen-Jung, Christine Kapaun, Boryana Ivanova, Florian Kaiser, Ludwig Fischer von Weikersthal, Nicolas Moosmann, Andreas Schalhorn, Martina Stauch, Alexander Kiani, Swantje Held, Thomas Decker, Markus Moehler, Jens Neumann, Thomas Kirchner, Andreas Jung, Volker Heinemann
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6559–6567.
https://doi.org/10.1158/1078-0432.CCR-20-2748
Published: 15 December 2020
View article titled, Amphiregulin Expression Is a Predictive Biomarker for <em>EGFR</em> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
Open the PDF for Amphiregulin Expression Is a Predictive Biomarker for <em>EGFR</em> Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials in another window
Includes: Supplementary data
Journal Articles

Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer

Pierre Laurent-Puig, Marie-Lise Grisoni, Volker Heinemann, François Liebaert, Daniel Neureiter, Andreas Jung, François Montestruc, Yann Gaston-Mathe, Raphaële Thiébaut, Sebastian Stintzing
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (1): 134–141.
https://doi.org/10.1158/1078-0432.CCR-18-1324
Published: 03 January 2019
View article titled, Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in <em>RAS</em> Wild-Type Metastatic Colorectal Cancer
Open the PDF for Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in <em>RAS</em> Wild-Type Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab

Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Dongyun Yang, Yu Sunakawa, Satoshi Matsusaka, Yan Ning, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Diana L. Hanna, Shivani Soni, Alberto Puccini, Wu Zhang, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Heinz-Josef Lenz
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (4): 784–793.
https://doi.org/10.1158/1078-0432.CCR-17-1663
Published: 14 February 2018
View article titled, A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Open the PDF for A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab in another window
Includes: Supplementary data
Journal Articles

The SpheroPCT study: The spheroid microtumor model is predictive for the therapeutic response of colorectal cancers

Barbara Mayer, Mareile Joka, Volker Heinemann, Ilona Funke, Karl-Walter Jauch
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (15_Supplement): B40.
Published: 15 August 2014
View article titled, The SpheroPCT study: The spheroid microtumor model is predictive for the therapeutic response of colorectal cancers
Journal Articles

Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

Clemens Giessen, Ruediger Paul Laubender, Donna Pauler Ankerst, Sebastian Stintzing, Dominik Paul Modest, Ulrich Mansmann, Volker Heinemann
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 225–235.
https://doi.org/10.1158/1078-0432.CCR-12-1515
Published: 02 January 2013
View article titled, Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials
Open the PDF for Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials in another window
Includes: Supplementary data
Journal Articles

Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer

Stefan Boeck, Michael Haas, Rüdiger P. Laubender, Frank Kullmann, Christina Klose, Christiane J. Bruns, Ralf Wilkowski, Petra Stieber, Stefan Holdenrieder, Hannes Buchner, Ulrich Mansmann, Volker Heinemann
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (3): 986–994.
https://doi.org/10.1158/1078-0432.CCR-09-2205
Published: 01 February 2010
View article titled, Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer
Open the PDF for Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer in another window